U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06849492) titled 'HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer' on Feb. 16.
Brief Summary: To explore the efficacy and safety of treatment for recurrent and metastatic advanced first-line triple-negative breast cancer guided by cell surface protein-based subtyping (HIM).
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Advanced Triple Negative Breast Cancer
Intervention:
DRUG: Camrelizumab
PD-1 inhibitor
DRUG: Nab-paclitaxel
chemotherapy
DRUG: SKB264
Trop2-ADC
DRUG: Lenvatinib
Anti-angiogenic TKI
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Fudan University
Information provide...